![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 28, 2023 12:09:47 AM
https://www.youtube.com/watch?v=ZLL_QdiepMo
Besides their highly expected great results from ALS Phase 2b trial to be released in December, they also have started the Phase 2 trial for Alzheimer's disease with very positive results from the phase 1 trial. As the CEO said on November 7, 2023, "In December, NeuroSense will unvail the clinical Top-line results of the Paradigm study (phase 2b trial), marking a major turning point in the fight against ALS. We are committed to sharing all results from this groundbreaking clinical trial with the ALS community." This company will be huge.
Recent NRSN News
- NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression • PR Newswire (US) • 07/09/2024 01:27:00 PM
- NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug • PR Newswire (US) • 07/01/2024 12:00:00 PM
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results • PR Newswire (US) • 06/24/2024 01:00:00 PM
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal • PR Newswire (US) • 06/21/2024 08:30:00 PM
- NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit • PR Newswire (US) • 05/20/2024 01:00:00 PM
- NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning • PR Newswire (US) • 05/14/2024 01:05:00 PM
- NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients • PR Newswire (US) • 05/07/2024 12:45:00 PM
- NeuroSense Announces First Quarter 2024 Business Update • PR Newswire (US) • 05/02/2024 01:19:00 PM
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease • PR Newswire (US) • 04/22/2024 12:30:00 PM
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 • PR Newswire (US) • 04/12/2024 12:30:00 PM
- NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 04/10/2024 11:16:00 PM
- NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics • PR Newswire (US) • 04/09/2024 12:30:00 PM
- NeuroSense Announces Year End 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/05/2024 01:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 01:25:59 PM
- NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial • PR Newswire (US) • 02/21/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 06:20:37 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 03:14:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:38:16 PM
- NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule • PR Newswire (US) • 02/07/2024 02:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:49:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:48:26 PM
- NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts • PR Newswire (US) • 01/09/2024 01:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/27/2023 10:03:10 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM